Novavax climbs on quarterly revenue beat

Novavax

06/05/2026 13:03

** Shares of vaccine maker Novavax NVAX.O rise 7.3% to $8.69 premarket

** Co's quarterly revenue of $140 million beats analysts' average expectation of $78.3 million on strength in vaccine deals

** NVAX says it is continuing efforts to reduce costs, targeting combined research and administrative expenses of about $325 million in 2026 and $225 million in 2027

** Co says it aims to cut those expenses further to between $150 million and $200 million in 2028, representing a reduction of more than 50% compared with 2025 levels

** Up to last close, stock up 20.5% YTD

 (Reporting by Christy Santhosh)

 ((Christy.Santhosh@thomsonreuters.com))